Full-Time

Senior Director

Consumer Marketing

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

No salary listed

Senior, Expert

Princeton, NJ, USA

70% in-office work required.

Category
Brand & Creative Marketing
General Marketing
Growth & Marketing
Required Skills
Market Research
Branding/Brand Strategy
Marketing
Data Analysis
Requirements
  • A minimum of 12–15 years of marketing experience, including at least 5 years of dedicated consumer marketing experience, preferably in the pharmaceutical or biotech industries.
  • At least 3 years of people management experience, with a demonstrated ability to lead and develop high-performing teams.
  • A Bachelor's degree in Marketing, Business, or a related field.
  • Demonstrated experience in leading teams, strategic planning, and the successful execution of large-scale marketing campaigns.
Responsibilities
  • Develop and execute a comprehensive consumer marketing strategy for the US Commercial organization, ensuring alignment with Moderna’s business objectives.
  • Lead and manage a team of marketing professionals, providing mentorship, fostering development, and ensuring the delivery of high-impact initiatives.
  • Conduct and oversee market research and analysis to understand the pharmaceutical consumer landscape, including patient demographics, behaviors, market trends, and competitor strategies.
  • Translate insights into action by developing innovative marketing campaigns to drive patient engagement and support brand growth.
  • Develop and manage robust brand strategies for Moderna’s pharmaceutical products, including establishing strong brand identities and messaging.
  • Maintain strict adherence to regulatory compliance, ensuring all marketing efforts align with industry regulations and ethical standards.
  • Oversee the consumer marketing budget, effectively allocating resources, optimizing ROI, and evaluating the success of marketing initiatives.
  • Utilize digital marketing channels to enhance consumer reach and engagement.
  • Lead cross-functional collaboration with internal and external stakeholders, ensuring integration of marketing efforts across all functions.
  • Champion the consumer marketing elements of new product launches, ensuring successful market entry and sustained growth.
  • Develop KPIs to measure the success of marketing strategies and adjust based on data-driven insights.
  • Represent the consumer marketing function within leadership discussions, providing insights and strategic recommendations to senior executives.
Desired Qualifications
  • Proven leadership skills, with a track record of managing and developing high-performing teams.
  • A strong understanding of the healthcare ecosystem, including consumer and patient dynamics within the pharmaceutical space.
  • Expertise in brand management, campaign development, and digital marketing strategies.
  • Robust analytical skills with the ability to leverage data to inform decision-making and optimize marketing ROI.
  • Demonstrated success in new product launches and market introduction strategies.
  • Experience managing large budgets and resource allocation in a matrixed organization.
  • Exceptional interpersonal and communication skills, with the ability to influence senior stakeholders and build consensus across functions.
  • A deep understanding of regulatory compliance and its role in pharmaceutical marketing.
  • A passion for innovation and a commitment to driving meaningful change within a fast-paced, high-growth environment.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for various biological functions. Their approach involves creating a new class of medicines that utilize mRNA to instruct cells to produce specific proteins, potentially leading to significant advancements in treatment options for patients. Unlike traditional pharmaceuticals, which often rely on proteins or antibodies, Moderna's mRNA-based therapies aim to enhance the discovery, development, and manufacturing processes of medicines. The company's goal is to leverage the unique properties of mRNA to improve patient outcomes and create a new category of effective treatments.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna plans to launch a cancer vaccine with Merck by 2027.
  • The company secured a $590 million contract for bird flu vaccine development.
  • Moderna's mRNA COVID-19 vaccine supply agreement with the EU spans four years.

What critics are saying

  • Moderna faces a high-profile patent lawsuit with Pfizer and BioNTech.
  • The company reported significant net losses in 2024, impacting financial stability.
  • Regulatory scrutiny may delay product approvals, affecting future growth.

What makes Moderna unique

  • Moderna is pioneering mRNA as a new class of medicines.
  • The company focuses on mRNA technology for personalized medicine and vaccines.
  • Moderna's mRNA platform enables rapid development of therapeutics and vaccines.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

4%
Assure Test
Mar 7th, 2025
Pfizer & BioNTech vs. Moderna: COVID-19 Vaccine Patent Lawsuit

The high-profile lawsuit between Pfizer, BioNTech, and Moderna over mRNA COVID-19 vaccine patents remains one of the most closely watched cases in 2025.

Bloomberg
Mar 5th, 2025
Moderna Eyes 2027 Launch for Cancer Vaccine Developed With Merck

Moderna Inc. expects to launch a personalized cancer vaccine that it's developing with Merck & Co. by 2027, one of its top executives said.

The Wall Street Journal
Feb 27th, 2025
Moderna Shares Fall After Reports of HHS Review of Bird Flu Vaccine Contract

Moderna was awarded the contract from the U.S. Department of Health and Human Services in January during the Biden administration to accelerate development of its mRNA-based vaccine, and as part of an effort to address growing concerns of a bird flu pandemic in humans.

Financial Modeling Prep
Feb 14th, 2025
Moderna, Inc. (NASDAQ:MRNA) Faces Challenges and Opportunities in Biotech Sector

Moderna is developing new products, including a next-generation COVID vaccine, with a revenue forecast between $1.5 billion and $2.5 billion for 2025.

PharmiWeb
Feb 14th, 2025
Moderna Reports Fourth Quarter And Fiscal Year 2024 Financial Results And Provides Business Updates

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizingReports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28)Expects 2025 revenue range of $1.5 to 2.5 billion andending cash balance of approximately $6 billionSubmitted three investigational mRNA products for regulatory approval, including Moderna's next-generation COVID vaccine, RSV vaccine for high-risk adults aged 18 to 59, and flu/COVID combination vaccineCAMBRIDGE, MA / ACCESS Newswire / February 14, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the fourth quarter and fiscal year 2024."We have made progress in 2024 across our late-stage pipeline and cost reduction efforts. Our team successfully filed three Biologics License Applications in the final months of the year and reduced our costs by 27 percent compared to 2023," said Stéphane Bancel, Chief Executive Officer of Moderna. "In 2025, we remain focused on driving sales, delivering up to 10 product approvals through 2027, and expanding cost efficiencies across our business. By the end of 2025, we aim to remove nearly $1 billion in costs. With strong momentum in our late-stage pipeline, we anticipate multiple approvals starting this year, along with key Phase 3 readouts that will support our long-term growth."Recent progress includes:Commercial UpdatesModerna is entering 2025 with two approved products, Spikevax® and mRESVIA®.COVID-19: The Company reported $923 million in Spikevax® sales in the fourth quarter of 2024, which includes $244 million of U.S